Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Acarbose has sex-dependent and -independent effects on age-related physical function, cardiac health, and lipid biology
Jonathan J. Herrera, … , Richard A. Miller, Michael Garratt
Jonathan J. Herrera, … , Richard A. Miller, Michael Garratt
Published September 29, 2020
Citation Information: JCI Insight. 2020;5(21):e137474. https://doi.org/10.1172/jci.insight.137474.
View: Text | PDF
Research Article Aging

Acarbose has sex-dependent and -independent effects on age-related physical function, cardiac health, and lipid biology

  • Text
  • PDF
Abstract

With an expanding aging population burdened with comorbidities, there is considerable interest in treatments that optimize health in later life. Acarbose (ACA), a drug used clinically to treat type 2 diabetes mellitus (T2DM), can extend mouse life span with greater effect in males than in females. Using a genetically heterogeneous mouse model, we tested the ability of ACA to ameliorate functional, pathological, and biochemical changes that occur during aging, and we determined which of the effects of age and drug were sex dependent. In both sexes, ACA prevented age-dependent loss of body mass, in addition to improving balance/coordination on an accelerating rotarod, rotarod endurance, and grip strength test. Age-related cardiac hypertrophy was seen only in male mice, and this male-specific aging effect was attenuated by ACA. ACA-sensitive cardiac changes were associated with reduced activation of cardiac growth–promoting pathways and increased abundance of peroxisomal proteins involved in lipid metabolism. ACA further ameliorated age-associated changes in cardiac lipid species, particularly lysophospholipids — changes that have previously been associated with aging, cardiac dysfunction, and cardiovascular disease in humans. In the liver, ACA had pronounced effects on lipid handling in both sexes, reducing hepatic lipidosis during aging and shifting the liver lipidome in adulthood, particularly favoring reduced triglyceride (TAG) accumulation. Our results demonstrate that ACA, already in clinical use for T2DM, has broad-ranging antiaging effects in multiple tissues, and it may have the potential to increase physical function and alter lipid biology to preserve or improve health at older ages.

Authors

Jonathan J. Herrera, Sean Louzon, Kaitlyn Pifer, Danielle Leander, Gennifer E. Merrihew, Jea H. Park, Kate Szczesniak, Jeremy Whitson, John E. Wilkinson, Oliver Fiehn, Michael J. MacCoss, Sharlene M. Day, Richard A. Miller, Michael Garratt

×

Figure 5

ACA reduces hepatic lipidosis and alters the hepatic lipidome similarly in both sexes.

Options: View larger image (or click on image) Download as PowerPoint
ACA reduces hepatic lipidosis and alters the hepatic lipidome similarly ...
(A and B) Liver pathology scores are from 25-month-old mice, with each dot representing a data point for an individual animals. (C–G) Lipidomics was conducted on 12-month-old animals. Sample sizes for lipidomic analysis were 7 female controls, 10 ACA females, 9 male controls, and 9 ACA males. (C) Heatmap of TAG species significantly changed in abundance with ACA treatment after correction for FDR. Each row represents a different TAG species, with rows ordered according to the chain length of each species (every fifth row labeled). Values for each species have been standardized before plotting, showing the number of SDs that each observation falls above or below the mean. Each column represents a value for a different mouse. (D) Changes in phosphatidylcholines in ACA-treated mice. Each row represents an individual species that differs in abundance with ACA treatment, with rows ordered according to number of double bonds. (E–G) Lysophosphatidylcholines (LPC), Lysophosphatidylethanolamines (LPE) (E), fatty acids (F), and sphingolipids (G) significantly altered in abundance with ACA treatment. Statistics calculated with a 2-way ANOVA, including sex and treatment as variables.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts